Medical Oncology
Supplementary information
Reduced frequency of NKT cells in patients with progressive chronic lymphocytic
leukemia
Farhad Jadidi-Niaragh1, Mahmood Jeddi-Tehrani2, Bita Ansaripour3, Seyed Mohsen Razavi4,
Ramazan Ali Sharifian5 and Fazel Shokri1*
1. Department of Immunology, School of Public Health, Tehran University of Medical Sciences,
Tehran, Iran
2. Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
3. Department of Immunology, School of Medicine, Tehran University of Medical Sciences,
Tehran, Iran
4. Clinic of Hematology and Oncology, Firozgar Hospital, Faculty of Medicine, Tehran
University of Medical Sciences, Tehran, Iran
5. Clinic of Hematology and Oncology, Vali-Asr Hospital, Faculty of Medicine, Tehran
University of Medical Sciences, Tehran, Iran
Running title: Downregulation of NKT cells in progressive CLL
*Corresponding author: Fazel Shokri PhD, Professor
Department of Immunology, School of Public Health
Tehran University of Medical Sciences, Tehran 14155, Iran
Tel: +98-21-88953021; Fax: +98-21-88954913
Email: fshokri@tums.ac.ir
Table S1: Major clinical and haematological characteristics of CLL patients
No
Patients
Age
Sex
WBC
×103
Lym
(%)
Hb
(g/dl)
PLT
×103
Rai
stage
Organomegaly
Disease
Progression
VH member
Treatment
Indolent
IGHV
mutational
status
Mut
1
CLL2
63
M
>100
88
12.3
216
II
HPM
IGHV3-30
-
2
CLL5
63
M
61.2
94
13.5
162
0
-
Indolent
Mut
IGHV4-4
-
3
CLL8
58
F
116.2
96
12.3
230
0
-
Progressive
Mut
IGHV1-8
-
4
CLL9
59
M
88.7
93
11.5
87
IV
HPM, SPM
Progressive
Mut
IGHV4-39
Chlo+Flud
5
CLL16
57
M
60
87
14.7
117
0
-
Indolent
Mut
IGHV3-7
Pred
6
CLL18
61
M
34.1
83
10.9
338
III
-
Indolent
Mut
IGHV3-7
-
7
CLL20
66
M
36.2
80
16.8
170
0
-
Indolent
Mut
IGHV3-7
-
8
CLL21
65
F
13.6
80
13.3
268
0
-
Indolent
Mut
IGHV4-39
-
9
CLL23
80
M
28.9
89
12.2
71
IV
SPM
Progressive
Mut
IGHV6-1
Flud
10
CLL28
53
M
26.1
89
13.2
163
0
-
Progressive
Unmut
IGHV3-11
-
11
CLL33
71
F
41.4
87
13.4
156
0
-
Progressive
Unmut
IGHV4-30
-
12
CLL34
60
M
7
74
12.7
108
II
LAP, SPM
Progressive
Unmut
IGHV1-46
-
13
CLL36
60
F
31.1
69
13.9
158
0
-
Progressive
Unmut
IGHV3-49
-
14
CLL38
51
F
37.7
85
13.8
203
II
SPM
Progressive
Mut
IGHV3-30
-
15
CLL43
67
F
41.8
84
13.4
217
0
-
Progressive
Unmut
IGHV3-11
-
16
CLL45
58
F
25
60
12
110
I
LAP, HPM
Progressive
Unmut
IGHV3-7
-
17
CLL46
40
M
116
94
14.4
168
II
LAP, SPM
Progressive
Unmut
IGHV3-49
-
18
CLL49
78
F
20
86
15.7
276
0
-
Indolent
Mut
IGHV3-30
-
19
CLL54
50
M
17.7
74
13.1
160
0
-
Progressive
Unmut
IGHV3-30
-
20
CLL55
82
M
170
89
13.4
173
II
SPM
Progressive
Unmut
IGHV4-4
-
21
CLL57
67
F
103
92
13.8
158
0
-
Progressive
Unmut
IGHV4-39
-
22
CLL62
50
M
53.7
88
13.6
150
0
-
Progressive
Unmut
IGHV3-7
-
23
CLL64
65
M
355
88
13.5
138
II
LAP, SPM
Progressive
Mut
IGHV3-7
-
24
CLL69
62
M
27
85
14.4
262
0
-
Indolent
Unmut
IGHV3-7
-
25
CLL70
53
F
22.6
79
12.1
223
0
-
Indolent
Mut
IGHV4-39
-
26
CLL71
56
M
18
70
15.6
160
0
-
Indolent
Mut
IGHV3-33
-
27
CLL72
74
M
37.2
78
15.4
115
0
-
Indolent
Mut
IGHV3-11
-
28
CLL73
43
M
83
86
15
131
0
-
Indolent
Mut
IGHV4-34
-
29
CLL74
47
M
10
70
15
176
I
LAP
Indolent
Mut
IGHV3-7
-
30
CLL75
66
F
21.5
80
11.7
187
0
-
Indolent
Mut
IGHV3-53
-
31
CLL76
54
M
137
95
11.3
213
II
SPM
Progressive
Unmut
IGHV1-8
-
32
CLL77
66
M
16.5
78
14
299
0
-
Indolent
Mut
IGHV3-23
-
33
CLL78
60
M
70
90
13.1
111
I
LAP
Progressive
Mut
IGHV1-69
-
34
CLL79
48
F
15.4
66
12.3
226
0
-
Indolent
Unmut
IGHV3-21
-
35
CLL80
76
M
12.8
90
10.2
87
IV
SPM
Progressive
Mut
IGHV3-73
Chlo+Flud
36
CLL81
60
M
102
90
14
156
0
-
Progressive
Mut
IGHV3-7
-
37
CLL83
54
M
20
75
12.6
161
I
LAP
Indolent
Mut
IGHV3-43
-
38
CLL84
64
F
25
76
12.5
155
0
-
Indolent
Unmut
IGHV3-11
-
39
CLL85
68
M
20
70
14.5
232
I
LAP
Indolent
Mut
IGHV3-7
-
40
CLL86
53
F
19
60
13.1
158
0
-
Indolent
Unmut
IGHV5-51
-
CLL: Chronic lymphocytic leukaemia, M: Male, F: Female, Mut: Mutated, Unmut: Unmutated, IGHV:
Immunoglobulin heavy chain variable region, LAP: Lymphadenopathy, SPM: Splenomegaly, HPM:
Hepatomegaly, WBC: White blood cell count, Lym: Percent of lymphocytes, Hb: Hemoglobin, PLT: Platelet,
Chlo: Chlorambucil, Flud: Fludarabine and Pred: Prednisolone; Treated patients were enrolled in this study at
least 6 months after completion of treatment.